Clinical Trial

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-17; most recent amendment 2026-03-26.
Status change: Recruiting → Active, Not Recruiting 2026-03-26
Trial Details
NCT Number NCT05866614
Lead Sponsor Celltrion
Conditions Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
Enrollment 881 participants
Start Date 2023-01-13
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-31